The Weight-Loss Drug Boom Hits Its Middle Age: What the GLP-1 Economy Means for Your Portfolio
The obesity drug market is shifting from scarcity to fierce competition, as new pills, direct-to-consumer pricing and looming patent expirations upend what was once a two-player race. With one in five U.S. households now including a GLP-1 user, we will break down what the next phase means for healthcare investors and…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
Similar episodes from other shows
More like InvestTalk →
Is Novo Nordic Unstoppable? Insight on Ozempic's Global Impact!
The State of Weight-Loss Drugs
Here's How the New Weight Loss Drugs Could Change Everything
#211 The Weight Loss Drug Revolution: The Hottest Trend on Wall Street
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.